Targets › IL12RB1
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. (UniProt, P42701)
Open in Phaseline: the race on IL12RB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kangabio AUSTRALIA | KGX101 Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion | IL12, IL12RB1, IL12RB2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2027 |
Advanced or Metastatic Solid Tumors (2)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.